

# **New Treatment Modalities of Acute Lung Injury**

Essay

Submitted for Partial Fulfillment  
of Master Degree  
in Intensive Care Medicine

**By**  
**Mohammed Magdy Mohammed Shalaby**  
M.B.B.Ch.  
Faculty of Medicine  
Zagazig University

Under the Supervision of

**Prof.Dr. Azza Abd Elrashid Hassan Fayed**  
Professor of Anesthesia  
Faculty of Medicine  
Ain Shams University

**Dr. Rasha Gamal Abu Sinna**  
Lecturer of Anesthesia  
Faculty of Medicine  
Ain Shams University

**Faculty of Medicine**  
**Ain Shams University**  
**2012**

جامعة عين شمس  
كلية الطب  
قسم التخدير

## الطرق الحديثة في علاج مرض الإصابة الرئوية الحادة

رسالة مقدمة من

الطبيب/ محمد مجدى محمد شلبي  
بكالوريوس الطب والجراحة  
كلية الطب  
جامعة الزقازيق

توطئة للحصول علي درجة الماجستير  
في الرعاية المركزة

تحت إشراف

الأستاذ الدكتور / عزة عبد الرشيد حسن فايد  
أستاذ التخدير  
كلية الطب  
جامعة عين شمس

الدكتور / رشا جمال أبو سنة  
مدرس التخدير  
كلية الطب  
جامعة عين شمس

كلية الطب  
جامعة عين شمس  
2012

## *ACKNOWLEDGMENT*

*First of all I would like to thank ALLAH for all the power and support he gave me to finish this work,*

*I would like to express my deepest thanks, gratitude and respectful appreciation to **Prof. Dr. Azza Abd El-Rashid Hassan**, Prof. of anesthesia, Faculty of medicine, Ein-Shams University, to whom I'm deeply grateful for her constant supervision and encouragement without which I would not have been able to complete this work.*

*Also, I would like to express my sincere thanks to **Dr. Rasha Gamal Abo-Sinna**, Lecturer of anesthesia, Faculty of medicine, Ein-Shams University, to whom I'm greatly indebted for her continuous interest and honest advices during the preparation and finalization of this work.*

*I would like to express my deep thanks to all staff members of anesthesia department, and my family for their support and help.*

## List of abbreviations

**ACE<sub>2</sub>** :Angiotensin-Converting Enzyme-2

**AECC:** American European Consensus Conference

**ALI:** Acute Lung Injury

**APACHE:** Acute Physiology And Chronic Health Evaluation

**APRV:** Airway Pressure Release Ventilation

**ARDS:** Acute Respiratory Distress Syndrome

**BALF:** Broncho Alveolar Lavage Fluid

**BMPC:** Bone Marrow Progenitor Cell

**C<sub>T</sub>:** Total Compliance of the respiratory apparatus

**C<sub>L</sub>:** Compliance of the Lungs

**C<sub>w</sub>:** Compliance of the chest Wall

**CMV:** Controlled Mechanical Ventilation

**CT:** Computed Tomography

**DAD:** Diffuse Alveolar Damage

**DIC:** Disseminated Intravascular Coagulopathy

**DVT:** Deep Venous Thrombosis

**ECCO<sub>2</sub>R:** Extracorporeal Carbon Dioxide Removal

**ECMO:** Extracorporeal Membrane Oxygenation

**ERV:** Expiratory Reserve Volume

**EIT:** Electrical Impedance Tomography

**eNOS:** Endothelial Nitric Oxide Synthase

**ESs:** Embryonic Stem Cells

**ETI:** Endo-Tracheal Intubation

**EVD:** Extravascular Lung Density  
**EVLW:** Extra Vascular Lung Water  
**FRC:** Functional Residual Capacity  
**FVC:** Forced Vital Capacity  
**FiO<sub>2</sub>:** Inspiratory Fraction of Oxygen  
**GST:** Glutathione-S-Transferase  
**HFV:** High-Frequency Ventilation  
**HFJV:** High-Frequency Jet Ventilation  
**HFOV:** High-Frequency Oscillatory Ventilation  
**HSCSs:** Hematopoietic Stem Cells  
**IC:** Inspiratory Capacity  
**ICU:** Intensive Care Unit  
**IKB:** Inhibitory Kappa B  
**IL:** Interleukin  
**IMV:** Intermittent Mandatory Ventilation  
**IRV:** Inspiratory Reserve Volume  
**IRV:** Inverse Ratio Ventilation  
**KGF:** Keratinocyte Growth Factor  
**LIS:** Lung Injury Score  
**MMPs:** Matrix Metalloproteases  
**MMV:** Mandatory Minute Ventilation  
**MODS:** Multi organ Dysfunction Syndrome  
**MSCs:** Mesenchymal Stem Cells  
**NAC:** N-acetylcysteine  
**NIPPV:** Noninvasive Positive-Pressure Ventilation  
**NFKB:** Nuclear Factor kappa B

**NO:** Nitric Oxide

**PAOP:** Pulmonary Artery Occlusion Pressure

**P<sub>A</sub>O<sub>2</sub>:** Alveolar O<sub>2</sub> Tension

**PaO<sub>2</sub>:** Arterial O<sub>2</sub> Partial Pressure

**PCV:** Pressure Control Ventilation

**PDGF:** Platelet-Derived Growth Factor

**PE:** Pulmonary Embolism

**PEEP:** Positive End Expiratory Pressure

**PET:** Positron Emission Tomography

**PFCs:** Perfluorocarbons

**PLV:** Partial Liquid Ventilation

**PN:** Parenteral Nutrition

**PTCER:** Pulmonary Transcapillary Escape Rate

**PVR:** Pulmonary Vascular Resistance

**Q<sub>va</sub>:** Venous Admixture

**RAGE:** Receptor for Advanced Glycated End Products

**RM:** Recruitment Maneuver

**ROS:** Reactive Oxygen Species

**RV:** Residual Volume

**SARS:** Severe Acute Respiratory Syndrome

**SIMV:** Synchronized Intermittent Mandatory Ventilation

**SIRS:** Systemic Inflammatory Response Syndrome

**SLB:** Surgical Lung Biopsy

**SP:** Surfactant Proteins

**TEE:** Trans Esophageal Echocardiography

**TGF-β:** Transforming Growth Factor beta

**TIMPs:** Tissue Inhibitors of Metalloproteases

**TLB:** Transbronchial Lung Biopsy

**TLC:** Total Lung Capacity

**TNF:** Tumor Necrosis Factor

**TPP:** Transpulmonary Pressure

**TRALI:** Transfusion Related Acute Lung Injury

**VC:** Vital Capacity

**V/Q:** Ventilation-Perfusion Ratio

**Vt:** Tidal Volume

**VWF:** Von-Willebrand Factor antigen

## List of figures

<b>Figure (1):</b> Bronchi, bronchial tree, and lungs -----	4
<b>Figure (2):</b> Alveolar-capillary barrier -----	13
<b>Figure (3):</b> Lung volumes -----	18
<b>Figure (4):</b> Effect of ventilation and perfusion mismatch on $PO_2$ and $PCO_2$ -----	22
<b>Figure (5):</b> Oxygen-hemoglobin dissociation curve -----	26
<b>Figure (6):</b> Normal and injured alveolus during the acute phase of ALI-----	40
<b>Figure (7):</b> Exudative phase of ALI -----	42
<b>Figure (8):</b> Fibroproliferative phase of ALI -----	44
<b>Figure (9):</b> Surfactant secreting cells -----	49
<b>Figure (10):</b> Resolution of ALI -----	54
<b>Figure (11):</b> Chest radiograph. Bilateral opacificaion of ALI in the absence of cardiac failure in a ventilated patient -----	63
<b>Figure (12):</b> CT scan. Typical CT in ALI showing patchy opacification, loculated pneumothoraces, and bilateral chest drains ---	65
<b>Figure (13):</b> Mechanisms of gas exchange in HFV-----	78



# Contents

<b>Introduction</b>	1
<b>Aim of the work</b>	3
<b>Anatomy of the lung</b>	4
<b>Respiratory Physiology</b>	14
Mechanics of ventilation	15
Control of breathing	28
<b>Definitions of ALI</b>	31
<b>Pathophysiology of ALI</b>	39
<b>Pathogenesis of ALI</b>	45
<b>Diagnosis of ALI</b>	55
<b>Management of ALI</b>	72
Mechanical ventilation	72
General supportive care	90
Pharmacological therapy	97
<b>Recent treatment modalities of ALI</b>	106
<b>Prognosis</b>	114
<b>Summary</b>	116
<b>References</b>	119
<b>Arabic summary</b>	

## List of tables

<b>Table (1):</b> ) Modified clinical definition of ALI -----	32
<b>Table (2):</b> A new definition for ALI / ARDS -----	33
<b>Table (3):</b> Calculation of the lung-injury score -----	35
<b>Table (4):</b> Predisposing factors and mortality incidence in ALI-----	38
<b>Table (5):</b> Summary of some histopathological changes in ALI ---	41
<b>Table (6):</b> Pro and anti-inflammatory cytokines -----	46
<b>Table (7):</b> Causes of ALI-----	55
<b>Table (8):</b> features shared by ALI and other causes of acute respiratory failure-----	71
<b>Table (9):</b> Master plan of mechanical ventilation -----	73
<b>Table (10):</b> NIH ARDS network lower tidal volume ventilation for ALI/ARDS protocol -----	81

# **Introduction**

Acute lung injury (ALI) is defined as an acute lung disease with bilateral pulmonary infiltrates in chest radiography consistent with the presence of edema, absence of clinical evidence of left atrial hypertension, and a pulmonary wedge pressure of 18 mmHg or less. Additionally, the ratio of arterial oxygen tension to the fraction of inspired oxygen ( $\text{PaO}_2/\text{FiO}_2$ ) must be 300 mmHg or less. Acute respiratory distress syndrome (ARDS), the most severe form of ALI, is defined by a ratio of arterial oxygen tension to fraction of inspired oxygen of 200 mmHg or less **(Rocco and Pelosi, 2008)**.

Acute lung injury is caused mainly by either **direct lung injury** (due to aspiration pneumonia, pneumonia, fat emboli, inhalation injury, near drowning, and reperfusion injury) or **indirect lung injury** (due to transfusion related acute lung injury (TRALI), sepsis, acute pancreatitis, burns, drug overdose, head injury, and trauma) **(Ware and Matthay, 2000)**.

Despite much improvement in the understanding of ALI pathophysiology and recent success in therapy, the mortality rate remains high at 35-40%. The incidence of mortality in trauma patients is relatively low (10-15%); the highest number of deaths was observed in patients with sepsis, pneumonia, or aspiration **(Phua et al., 2009)**.

The course of ALI can be described in three overlapping phases. The acute or exudative phase starts from the 2<sup>nd</sup> day and lasts for up to 7 days from onset and is characterized by the development of hypoxemia, infiltrates on the chest radiograph, and a reduction in pulmonary compliance. These clinical changes are accompanied by leakage of protein-rich fluid in the alveoli, hemorrhage, and diffuse neutrophilic

---

alveolar infiltrates with resultant endothelial and epithelial injury (**Brun-Buisson et al., 2004**).

The sub-acute or proliferative phase of ALI occurs from day 5 onwards. It is characterized by persistent hypoxemia, increased dead space, and reduced lung compliance. This is accompanied by interstitial fibrosis, and disruption of capillary function. In some patients, these changes resolve and clinical improvement follows whereas other patients progress into the chronic or fibrotic stage. This stage results from widespread pulmonary fibrosis and loss of the normal lung structure leading to worsening lung compliance and an increase in dead space. This chronic stage usually starts as early as 14 days and lasts for many weeks (**McCallum and Evans, 2005**).

The goal of treatment for ALI/ARDS is to prevent further lung injury, reduce lung edema, and maintain tissue oxygenation. Treatment may be non-pharmacologic or pharmacologic. The non-pharmacological treatment includes: mechanical ventilation with lung protective strategy and fluid management strategies. The pharmacological treatment includes: anti-inflammatory therapy, beta-adrenergic agonists, anticoagulants, vasodilators: either non-selective (nitoprusside, hydralazine) or selective (prostaglandin E<sub>1</sub>, prostacyclin), corticosteroids, phosphatidic acid inhibitors, and anti-oxidants (**Briel et al., 2010**).

New modalities in treatment of ALI include: extracorporeal membrane oxygenation, surfactant, inhaled nitric oxide, pentoxifylline and lisofylline, hydroxymethylglutaryl-coenzyme A reductase inhibitors, activated protein C, endothelin receptor antagonists, prostaglandin I<sub>2</sub>, antibody to tumor necrosis factor (TNF), recombinant interleukin (IL)-1 receptor antagonists, anticytokine therapy, and cell based therapy (**Craig et al., 2011**).


---

# **Aim of the Essay**

The aim of the present study is to focus on the recent treatment modalities of acute lung injury.

# Anatomy of the lung

The lung is the essential organ of respiration in all air-breathing animals. To completely explain the anatomy of the lungs, it is necessary to discuss the passage of air through the mouth to the alveoli. Once air progresses through the mouth or nose, it travels through the oropharynx, nasopharynx, the larynx, the trachea, and a progressively subdividing system of bronchi and bronchioles until it finally reaches the alveoli where the gas exchange of carbon dioxide and oxygen takes place **(Wienberger et al., 2000)**.



**Figure (1):** Bronchi, bronchial tree, and lungs **(Rogan et al., 2004)**

Humans have two lungs, with the left being divided into two lobes and the right into three lobes. Together, the lungs contain approximately 2400 km of airways and 300 to 500 million alveoli, having a total surface area of about 70 m<sup>2</sup> in adults. Each lung weighs 1.1 kilogram, therefore making the entire organ about 2.3 kilogram. The conducting zone contains the trachea, the bronchi, the bronchioles, and the terminal bronchioles. The respiratory zone contains the respiratory bronchioles, the alveolar ducts, and the alveoli. The conducting zone has no gas exchange with the blood, and is reinforced with cartilage in order to hold open the airways. The conducting zone warms the air to 37 degrees Celsius and humidifies the air. It also cleanses the air by removing particles via cilia located on the walls of all the passageways. The respiratory zone is the site of gas exchange with blood **(Walter, 2004)**.

### ***Anatomy of airways:***

The larynx lies at the level of upper cervical vertebrae, C4-6, and its main structural components are the thyroid and cricoid cartilages, along with the smaller arytenoid cartilages and the epiglottis, which sit over the laryngeal inlet. A series of ligaments and muscles link these structures, which, by a co-ordinated sequence of actions, protect the larynx from solid or liquid material during swallowing as well as regulating vocal cord tension for phonation. The technique of cricoid pressure is based on the fact that the cricoid cartilage is a complete ring, which is used to compress the esophagus behind it against the vertebral bodies of C5-6 to prevent regurgitation of gastric contents into the pharynx. The thyroid and cricoid cartilages are linked anteriorly by the cricothyroid membrane, through which access to the airway can be gained in an emergency **(Albertine et al., 2005)**.

---